

## Technology Advisory Committee C Interests Register

**Topic: Zanubrutinib for treating chronic lymphocytic leukaemia [ID5078]**

**Publication Date: TBC**

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Michael Chambers	Committee member	Financial	Michael has participated in an advisory panel for Pfizer in an unrelated disease area (prostate cancer) and has provided advice on economic modelling to Sanofi in an unrelated disease area (COPD)	21.06.2023 & 18.08.2023	It was agreed that his declaration would not prevent Michael from participating in discussions for this appraisal.
Dr Richard Nicholas	Committee member	Indirect - financial	Dr Nicholas has attended paid advisory boards with Roche for an unrelated condition - multiple sclerosis	26.06.2023 & 08.09.2023	It was agreed that his declaration would not prevent Dr Nicholas from participating in discussions for this appraisal.
Elizabeth Thurgar	Committee member	Financial	Elizabeth has worked with AstraZeneca (comparator company) in unrelated indications: lokelma (hyperkalemia) and dapagliflozin (CKD).	21.06.2023 & 18.08.2023	It was agreed that her declaration would not prevent Elizabeth from participating in discussions for this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Kate Ren	Committee member	Financial	Dr Ren has attended an advisory board meeting for this topic last year.	21.06.2023 & 20.08.2023	It was agreed as a direct financial conflict Kate would not attend any discussions for this appraisal.
Professor Francesco Forconi	Clinical Expert	Financial	Professor Forconi has participated in an advisory board for BeiGene, received Honoraria, Speakers Bureau and travel and accommodation fees from Abbvie, Janssen-Cilag, BeiGene and AstraZeneca.	21.11.2022 & 12.09.2023	It was agreed that his declarations would not prevent Professor Forconi from providing expert advice to the committee.
Dr Rosalynd Johnston	Clinical expert	Financial	Dr Johnston has attended a meeting and fulfilled a paid speaking engagement for AbbVie in January 2023. she attended a meeting in April 2023 which was funded by Beigene where an invited group of UK CLL specialist doctors and scientists met to discuss future research and has received financial support from Abbvie to attend the ICML Conference in June 2023.	18.11.2022 & 12.09.2023	It was agreed that her declarations would not prevent Dr Johnston from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			Dr Johnston also noted that her nominating organisation, the UK CLL Forum, has received funding from the manufacturer BeiGene and comparator companies AbbVie, AstraZeneca, Janssen and Roche.		
Nick York	Patient expert	Financial	Nick is employed as a Patient Advocate by his nominating organisation Leukaemia Care, which has received funding and honoraria from comparator companies AbbVie, AstraZeneca, Gilead, Janssen and Pfizer.	02.03.2023 & 12.09.2023	It was agreed that his declarations would not prevent Nick from providing expert advice to the committee.
Steven Lloyd	Committee member	Non-Financial professional interests	Steven has undertaken advisory work for Pfizer and AbbVie in unrelated areas around vaccinations and women's health.	22.08.2023	It was agreed that his declaration would not prevent Steven from participating in discussions for this appraisal.